Medexus Pharmaceuticals (TSE:MDP – Get Free Report) was upgraded by investment analysts at Ventum Cap Mkts to a “strong-buy” rating in a report released on Wednesday, Zacks.com reports.
Medexus Pharmaceuticals Stock Up 1.2 %
Shares of TSE MDP opened at C$1.74 on Wednesday. The firm has a market cap of C$42.56 million, a price-to-earnings ratio of 4.35 and a beta of 1.82. The company’s 50-day simple moving average is C$1.67 and its 200-day simple moving average is C$1.87. Medexus Pharmaceuticals has a 52-week low of C$1.30 and a 52-week high of C$3.53.
Medexus Pharmaceuticals Company Profile
Read More
- Five stocks we like better than Medexus Pharmaceuticals
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Albemarle Stock: Strong Fundamentals vs. Lithium Volatility
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- MongoDB Stock: Analysts Recommend Buying the Dip
- Stock Market Upgrades: What Are They?
- UniFirst Stock: Value-Building Sends a Signal to the Market
Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.